# Evaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

> **NCT03418571** · PHASE2 · TERMINATED · sponsor: **Ablynx, a Sanofi company** · enrollment: 15 (actual)

## Conditions studied

- Respiratory Syncytial Virus Lower Respiratory Tract Infection

## Interventions

- **BIOLOGICAL:** ALX-0171 1.5 mg/kg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03418571
- **Lead sponsor:** Ablynx, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-01
- **Primary completion:** 2018-10-24
- **Final completion:** 2018-10-24
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** The Sponsor decided to discontinue ALX-0171 development (due to insufficient evidence of efficacy). As a result, the ALX0171-C203 study was early terminated.
- **Last updated:** 2019-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03418571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03418571, "Evaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03418571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*